pdf   xlsx method abbreviations

mNSCLC - L2 - all population, ... , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.98 [0.85, 1.14]< 10%3 studies (3/-)58.3 %some concernnot evaluable moderatecrucial-
progression or deaths (PFS) 0.93 [0.61, 1.42]< 177%2 studies (2/-)62.6 %some concernnot evaluable moderateimportant-
DCR 1.00 [0.76, 1.32]> 10%2 studies (2/-)50.8 %some concernnot evaluable moderatenon important-
objective responses (ORR) 1.04 [0.78, 1.37]> 10%2 studies (2/-)60.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.